Abstract: A display device (1A) according to the present invention includes a first light source, a first retro-reflective part disposed at a position in an emission direction of first light emitted from the first light source, and a first light-separating part configured to reflect a part of the first light that has passed through the first retro-reflective part as a first reflected light and transmits at least a part of the first reflected light.

Abstract: A display device (1A) according to the present invention includes a first light source, a first retro-reflective part disposed at a position in an emission direction of first light emitted from the first light source, and a first light-separating part configured to reflect a part of the first light that has passed through the first retro-reflective part as a first reflected light and transmits at least a part of the first reflected light.

Abstract: A display device (1A) according to the present invention includes a first light source, a first retro-reflective part disposed at a position in an emission direction of first light emitted from the first light source, and a first light-separating part configured to reflect a part of the first light that has passed through the first retro-reflective part as a first reflected light and transmits at least a part of the first reflected light.

Abstract: Disclosed is a sustained release preparation which releases a poorly soluble medicinal agent in a pH-independent manner. Also disclosed is a sustained release preparation which is capable of controlling the Cmax of a medicinal agent to an adequate amount and is thus capable of maintaining the level of the medicinal agent in the blood to a level at which medicinal effects can be expected for a long period of time. Specifically disclosed is a sustained release preparation which is characterized by containing a pharmaceutically acceptable salt of 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone, and hypromellose. An organic acid is blended in the sustained release preparation in an amount of less than 1% by mass.

Abstract: Disclosed is a sustained release preparation which releases a poorly soluble medicinal agent in a pH-independent manner. Also disclosed is a sustained release preparation which is capable of controlling the Cmax of a medicinal agent to an adequate amount and is thus capable of maintaining the level of the medicinal agent in the blood to a level at which medicinal effects can be expected for a long period of time. Specifically disclosed is a sustained release preparation which is characterized by containing a pharmaceutically acceptable salt of 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone, and hypromellose. An organic acid is blended in the sustained release preparation in an amount of less than 1% by mass.

Abstract: The present invention provides a pharmaceutical composition comprising N-(3-chloro-4-morpholin-4-yl)phenyl-N′-hydroxyimidoformamidine and sulfobutyl ether &bgr;-cyclodextrin or a salt thereof, wherein sulfobutyl ether &bgr;-cyclodextrin increases the solubility of N-(3-chloro-4-morpholin-4-yl)phenyl-N′-hydroxyimidoformamidine and improves the photostability.

Abstract: The present invention provides a pharmaceutical composition comprising N-(3-chloro-4-morpholin-4-yl)phenyl-N′-hydroxyimidoformamidine and sulfobutyl ether &bgr;-cyclodextrin or a salt thereof, wherein sulfobutyl ether &bgr;-cyclodextrin increases the solubility of N-(3-chloro-4-morpholin-4-yl)phenyl-N′-hydroxyimidoformamidine and improves the photostability.

Abstract: A preparation for nasal administration which comprises as an effective ingredient a prostaglandin derivative represented by Formula (I): wherein X is a halogen atom, R1 is a C3-10 cycloalkyl group, a C3-10 cycloalkyl group substituted with C1-4 alkyl group(s) or a C4-13 cycloalkylalkyl group, R2 is a hydrogen atom, a C1-10 alkyl group or a C3-10 cycloalkyl group, m is an integer of 0 to 3, and n is an integer of 1 to 4 or a pharmaceutically acceptable salt thereof and a water-soluble polymer.